<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Systemic anaplastic large cell lymphoma: Response-guided induction therapy in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Systemic anaplastic large cell lymphoma: Response-guided induction therapy in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Systemic anaplastic large cell lymphoma: Response-guided induction therapy in adults</div><div class="cntnt"><img src="data:png;base64,iVBORw0KGgoAAAANSUhEUgAAAbkAAAHVBAMAAACeTJg6AAAACXBIWXMAAAPoAAAD6AG1e1JrAAAAJFBMVEX///8AAACGhoZISEgpKSm7u7ucnJxmZmbe3t4QEBDu7u7Nzc0seaxjAAAXfElEQVR42uydz3PbxhXHH34QpMgLHwn+kHSBArqpxheQdqtMfQFoW1blC+G447i9gIo0HjUXsHbrNL2QlmaaTi+SW7OpfaEseVq1F3ImnUTTf667ACmTslzJFEERzHsDWRZAfokP3nuLXexyF4CMjIyMjIyMjGzQ8MI2yXTJiwoIREd0REd079KVTjuk9/3fzoSUTkZMnUlXZhiYFg3YBNGFeBG1LFRFTE++7yLJs333gmE49n/z7JWMTl6NmJzO3NbCQHcdXX1hC1clXAW4jwXtcMNK6RErK+I8wIL6HZqMbr1Vjs1zuk4LwKOT3DDQXYvkC5VCq8w2gOegmOszGugzzqbgACTmo0bGi8x2QTQaiJn7fiVHNI+cUERmLK9DDXNsg1ge4i+WG3XQGcgz6yvGGjE5nSOZe986nu/qvu/Yq0NDV2jxjfsOCju+79hfTeY7yfDpDOnnLS/vVrp5B+GhkzDLNoCHqO1pkV2ed+ohT8QFte1FptpWmLMYXaw4q4WF7hR72JrmukqZamJER3RER3RER3REF1K6T6aZTi+bYaeLWdr73qCkQ+s7AW97v0Wjf28RtRpmWWP8Ia6Afie0vhOcRe+3NOC6pcj8U/CfIpXDnHeC03mGd4V1xC38mW1XrRwyTy1Bs0sXXw5zmSk4T47aumBIWuFfZVsTtCdfs1b5kpJnkcnpakao6fBuFVWhImlP4WMbhIoOGZ53Ti8yl8LtOzhqA6fjvuvRMSSf7nO4GXI6EXOcTmJ510fnR+a3rMykmhjRER3RER3REd2E2XSPpAreuURHdERHdERHdEQ3YhMwWLtkulDLEx3RER3RER3RkZGRkZGRnW37mBIwdfyniGkR1fqo1OPFWa3WHcjDTcJUFNXK2Ohute4LTrV1TGduf2TK2qjURVMxnkKtfUzn2t+50flxwSXmuuOIYlZKLOXZ6Ui/MQ9GR7fCR0VIWk9ecmceuad/7S0Ii5jdMWCScXTvNr/YR2v8K0qjiszfq85TPrisKy+51T+6A9/fC9Z3eUb3RRNAdqQ1g+ddTjSfjPADlDnPd115CbPRMfoObtVZ3m222cXt3ON0Jttkd1Tqkqa8ZHlX78lLLkTdaH5sdFv4XHBYevDE6NHFyiPLO0ut1PAu9OQ5HaptulWRkZGRkZGRfbDR01qiIzqiG6XF2gJ8P7V08XT187npjcwaoju9dB3E9vTSSZie4jJT4bPfTO8dYXdnmukWtGmma9SnmS4y1TWxkFX0Ah5vmbxcumSwziA6oiO6Hyrd4KQh3gdVTsy1wWdbPLb+ntGF5ETTsVZb6XS6jN3Xf/0eungGwMaUrMFjkBxIWOqVPDyW/BEgk+A7ofI+39ln+y7Bdtv1RdGMNzndn1zxJ5zOtduTQ3dLfZPJLqhttrF2Ti5mYaWIWsZS9chukx39J6pv2GsXsFOxX+N8ScS7+8gaDMX0AWuu23U9nlF2OF2BXQaPzpv7dELoVg43UolX4o1Xnher+4Zwb8WPzBlt8/XKoQONjSQkMhB1n3YqUDpq63aL5evqwRXuO8y1SpJWZZWTjxkdYlpyq/UJikx5I6kgLiOaoFi47QgPXJ+uUReeGfIXRWR0igmRb/LrLDKrqIqzGmMVf+tF5oG2ydoPfb7z27kTRJd4BWwDkLXqltG5t3rA6FrMd4uvDfmRuef7Dq4bvu+8cSw93zG6mZvg5Z3RzTuYMDqWVS7bQETrz5b1S+uvWubAzzt2dNfa8PKuXa2IXt7lbP58rJh+40VmuiVmPbpIt8ycHLoPMj1A+UunizWpJkZ0l0x3B06pwLyTht6c3eGjU8x3ypBjOr3vn1Io6WTn/b7rp1sPJV2jxW5s+rZWaIGEzZeiWZwVKkX131YaYpjbxh9jroquDnvtMNLd59Of6bG/rAAU6rAsr62AcG9V/sgP2GuJFzofFauDXAknnWh9pUPV8aaq09ejLggPEL8sLnO6ZfgpC0rMh5WuwdoAzWPfHZZFz3fsQIFv1xKZApSVfFgjU3YOcZXl3XWedzviS/DyDtd47f+I5Z12lFtQ82EtVZSBG9mJhyxw+jOWsN7N336V5ISF9G5O9UyiIzqiIzqiIzqiI7qx0A35RUyv1+vd7rHJoYvPK/PKTunt45IBy7xL47UWSkKFP2Tp0p28Nrzbr4rOJPiuLD7vnd+56LonUjnLd+LOJNDpsi5r19Gt4peYA2UHEnM1dBawDfv4N8xbansBjfvMEzFUD9BkvlPRKdWw8Vmvx9IoyXhXxLRk5WJWStlN2ezHax9ePt3R4eFe+1ok7z0CYoG6/syAqMm73+wW9518NSsaTUYNXg8lo0uJph+Zfo+l5/lyx9Elw94yjj7VwGbRG3/SngS6GV0u8LUjvUdA7DSXH2uLaBZyLRBntUy8hr8zxU8Q85Dweij5YAHFo/tVt8eS0f0Dc+ugS1pj25E2rBt2xLoRy09EmSk9F59zurKSL7A9i+7fv8+yBjfv907ks8qc/Id5yeA9P1Fzb2PumM4RHvg9luxoqdq602lfY3RbvO9yye6tY3H5dOK8kuV0C2r+KAfQqRSgqK7uqi2w0a2xvHNrKss7EyK71q8ts0sXxcYv/B5LdrS0jXeieJPRfW2lJLxrs58J8d05rNuTeoYthbOuUjzPZCrSKQtzUE2M6IiO6IguPHTTPWIfJurjiY7oiI7oiI7oiG44yclZykEIjz8EoiM6oiM6oiO6CaKbICM6oiM6oiO68dIpu+n/JPv+lvi4Gd9sVcD60KrtzIDq2tuJ4wTsVKA8Fro9Z3+jn65vGFUkeXL8zYeoOplB1b7BPRnJjcyNh04DGVdQbRVR43MDcLrIblPSzQvRaRDF/ICqfrxgBGSUl1FjPJFZzPExQo21b6Sr3twAjG5G29xfuZDvmGorM6iqHy8YwVSbh5UxlSoHV5KJIj5ypR/xuQE4XaMubGkXomOqWmZQVT9eMIKp6uvjKVU+bR9cmYuae2urB1dfdfNuRlvcvxgdU9Wyg6qe77wVHZhqpzweui1Mx63bfGiNqvG5AXiZyfNOu1CZyVShlu1X5WVmd0UHpirnYUyReRxLThB3reFVR0oXzGyYF1ClugrRER3RER3RBUZHT2uJjuiIbpQW1IoOQ+mOnC6oFR2G0h19GAW1osMwuqOnC2pFh2F0R08X1IoOw+iOni6oFR2G0Q2g+A5qRYchdAOgC2pFhyF0A6ALakWHIXQDoAtqRYchdKl951tQ3wwJciDn+emSo7+0yWB0BaIjOqL7AdJF3P9PZw/byLW0y6eL3bnmvKUrol/J8uYfyfTT+bOunOty+efHhwpckE46rS3SnRVFxBM7Tjc50+e7pch8/xkO0J07GPz38g7fIel613iz9X66vUrv1Lo7Ism3J80Eaphi99vP7tzs890SNB/OOptY4J3/Gdt6FbEwashOcbaGjUox/UadbYNoqVY2ilnJyvWWk1DZgWIqZuXEW95MLZHdZhXrw9L1rvGpE8d3YTond/Qv0MEEnvrvH8i7JSX/XHlZYi+Nopv5H3vn89Q2dgfwZ8m/gIu/IBmBL/JYbMvkIgtvnCYXyZM4iblYWzo73OQ02W66F9OE0Nlc7ODpJNtLwjSellzcKdtdeiLddNruX7fv+2QDMS4gYYHkvpcZEoxi83nf99X74efPs+vlKdWmdKjtrcc+q+0tyWKTCPfa6hNCnoq63SKNv5lo9F2S43pDbL7657193A+E20j8x47W8Ro4RhHwTA6jpMFt3DPFqhB9Nzh/vmnN09jRuuzRBypppQMluJPpgKpZNfYEW8dq5yjvvlSIsubux5JtstVuId1vmkj3OR4IkaJ0eqxeEN5Iotr+g3ucBMBmRlTtOMADdmDBYBuJX7qk0k2+LrUKM7mUXmppL2dpEgtYheJzWdCtrPaPik2srC3c2/+KPkDpVljLXJl5q33TZU+wQafYw3RlQnaEXSJuLvbpptS8YK5j7BwWu0O6tqOhUqZ/nAR9bkqHcaV0i4fbSHzn3ZcAikEKSTNh4vYRSkBSWIWpZyY2xC3yM8w5m77aFyajqzI6pkuu4hM4o2JH6WjeFaUfLdOlS4KVtu7TvEu5eXdIJ8JtSveCHSdRR5UOpaMp+EKPo6mlv43Ed8skXbYrhvlr+nQCVmEKfTeEsNi5dF/RB8oCxm4RYyczujJTRZ+g87dG1hpzb05/uTVgQcO869MRrMIU+m5Y3g3oHPqALdG8u2mxvBvQjWqZfkYD7ulHfCTG6S6L7mRfakw+XWL45a1W0iTTdPBTPTFgiz5d4k8qpYvXEmY1IrFz5X3tA/s7NppMW3Mi1NjRcDgEPbY1WYBc6rpJ6d7TAS+L3a9wJBr22FXe0w67WXZHk9s60XoVrWVg+DB2h5uIYw7Z/+1bSrdGBnTyMUVZOOlceV/iz4o7muw4tHOc38KWiUPQY5uIBevrBsxj7FoDOhzNhJvOlfeR27o7mmSxw+EPTts2P9qaTLoGsf9O8+6em3dRoHPlfaRRd0eTLzHvsnsLFZyG/Hh8a/I+rOZInIbx58UF1YJMJOjOUc61iTiqdOd7+5WPxDzSGRNGl4cbQ3SnrmCNeN/7VDpj1JIXPlq4DLrUavpTL3SELJ9KZ4ymEwdLnQXSN0kXPlrUtcmJtalx0KGHdn3BYUtHJWjiia0b8AJW6cvnt6H2AXQJHHoB/dljUItS7+RBP57oRsbOHo7tuOhidJywk9xlS0crMzk8sTVWp18I0eo4giJkVnhNL1hJKAYuLanfrZ5GRxuuUWpAU7P6FYPO6JiVbfSX3TKFhAWCTuuK/oO2ce1NrQ01S7IHy5mr1tx4Y5dWiMKWHwySxRNbY3X6BSuXjqC2JUdOKPQCI62szf0boHnyXf2h2JVaJLmofdN1Kwad0TGVDlri8KAWX8oUplRbwHosTDmP2RIOSWdpyxwsZx6dIzSWvLuT/nRH2HXpkgqe2Bpz8NhWSkdHUEQwZcGkF1A6Iv6uduY906B/mGK66lYMOqNj9YfYMtmyW6Hdslk9FtoALfoi5R8A6QbLmelidZz3zA34PU0rRkdnJnhia4rm3TzS0RFUHhyQ6vQCSleUDorgnBk7wz1lrOpWDDqj+3Rs2a2Ai5xYjwV24nIh3X06nbV7x5YztYD6u9GdnXyupxw8byNrEHbKWNWtGHRGU7okyzt4lCkkwWL1SPNOYjb3dSm7Jx0uZ1YOe5ww0p3jv2qnzuGjMxIbRSfA2wmh4+uZnI7TcbqI0032Hj8fVXflhdNxOk7H6Tgdp+N0//N/XdbhFFdDd7GhJafjdJyO00W0cDpOx+miQCeYMzmfL5bX42rI6aYrvn/F5W7o6ci69r01jwcfey7a8p4raQ0xXUoWm69+8BMEbf/ptdw5dLNXSZfIxAEeWbd80AnwiZkwQ07H9rGWfdAR6xr7zEmo6dIWbMOqH7pG6POO9+acjtNxOk7HVx44XeTp/GsW/0gyM62Q0/nXLP71erbYC3vL9K1ZTAHuTg05nW/N4gxALvR0/jWLRdBDT+dfs9g4OioovD2Cb83i1EIE+jvfmkVhNgJ0vjWLaSUCdP41i3U+R7gkOl87I2OXeAj2hegyfp4tFp52xOk4HacLP93pH9yNMl26KDmTSxevCbnJpXvfI0bMygqQQ5tfqTLd7QzN0aNM1yBkK6YuxxzCbH6aYJbT7yYrdnX7hfWc2fz21xxraBob/bzTCOkym1/qfq/sLe9Y0g4baY0w3TPhzj7UmM0vPUs6oJxGJ8BcAqT+fcjoO2jtvjVUtsNF57k3F8zOknL4Gf4B3eCn0acTNxVRJ8nXZGbR2IA2ChpslDWUFlqyJQ10YVGl++8jmGuR6dzDFzq2TFVjdCtJOa7SljnQhUWUDuYTyuMWIZXqE5Xl3UNGZ6CRldINdGFRjR1JKEKNkOXmXw6MmDNE1zvUhUWXjqzQnpL2IwY6aI/T7UkDXRifAV0aXQdU23YmlW5l5q2tTmzsquS6PdaW2TZDFTvZE518yiiTFU0OWd6dlw5NWB/RDZ8rsCEdkGo5wvfM02Mn6sndRi9idEapg5q0pUwH5AbZQjlYnTAlWB7+Y82nIJt8M4tz+1RTbLqbwSNEV2rRiTv6ZlcI0qEcrE6YEixLxOarA/JUVAm9ZKbUax+484gQ0wn4Xvrx2BE6cUffbJXRMTkYYUowbX4P4MEbKWHdopckTZIHkK+eTlRPufQ9/HKIDm8V4ib69e2Xd5kcjDAlGJn6dZO0HTpdKJevur9Lzh+CnaSjLaoyXQQNYPYkHZ24F6V/ZT5Isrhwl8nBCCrBbr6Rvsd91bdFWKWXJM2rpBN/0TudDn3b9L4vDNFFY6zS/uDQoX0DHuG5EXkJzx9ZX3AqaeUD6IwOfdvYq8WiSKcJehttenhey7Vc6lZW0HeSu5ROY7cSmF0jEaazQGF0eF7LJ2aiago3FKJQum3JcWPXii5dYpHQSXUJY7dMYyfeyon6jrBbFhREY3l3j+VdJOlSOnkswO3kYd5tSJh3tqTkwY1durigRrZlnhwXNid4bl6UWpO98sDpOB2n43ScblSZ7D1+4y+ZS301TsfpOB2n43ScjtNd5InDYGaMhaLaOB2n43ScLhqF03E6TjchdN40jQGaGQOh86ZpDNDMGEzL9KRpDNDMGAydJ01jgGbGYOg8aRoDNDMGRedB0xigmTEoOg+axgDNjLy/43ScjtNxOr7ywOk43cjiSdMYlJnRvyvyrBmeF01jUGZG/67Is4oXTWNgZkbfrsizihdNY2BmRt+uyLOKJ01jUGZG/67IM4onTWNQZkb/rsizihdNY2BmRt+uyLOKF01jYGZG367Is4oXTWNgZkbfrsgzFx+8XFwPwy/xf1dioTkYO4jdFd7HqZkgh81jHq9zOk7H6a6UTjg5FE5kIk83GIkLOiqK+l4tl20S6JqvnKPYHZM0Tgjd+wOLfZjZiMPqBrTrxblvpYUDEoc79K+8dJC9uwFOCZqV6W4EW+YOIfFrMmuZFdoyP6vtLcliE2Mni8/fCTptuSlzZSb3ED86HzW6ryvTG/DMpHTM5hD7vClsZlKMLpN6BmDKZBnFf9n9NSeKeffFYvx5TtQNtDk4LHaMbpHSPX9HiJzOCqaRVIT7Y8u7zuyl0SWyltTckHSjA3dTbt4h3bR1h/6Vh6ZMipJZBHV61jdd8tiHoNBA8yRkvTlNysTuBWJ3ZMSzP/ouNHRs141/ukJ+G2ptqFkSDaVCG4icDQ3dRfs7g2h1rVch6SyLnUCTe5ZMEF0BpY0/gEuXwhvzFdElMoHQaT3ydDpr9/qxmzA6EbLrUnZPwu/wxjw5dGGZ3wn3pW8zT0j1w8i3ByJPhylB6bTJjJ0ubiId2nMmke7Vo4yW6JJDVfTF6BJQDxMdzCUyHambh/HE7mhjsfzxD/IOvgORhxtblxq78fbmU/XRdD+1c/YuDQNhGH/z0SbV6TRpo1PKZemWCH6MjcWCuORcpFsUih9bJh0v6OLmB1ZH127tmP/O9wh1UQThTG25Zw0Efrz3vPfcy3ErzyHS6Uf29oLSMXaGx32HtnPxLPirSJfvzZ5b24TVeL3+5iFdAxdIlXQSkxjziwnVkiDBeBlwcLEd++twjccr9LThbyGdxheXDk6JoyUUMF4igovpEk+Lg5yDHfVz4lRdOyqZrpiAoMN4ibVritq5YPTEtyCA8QX67qAa39Hv6Ri3QmyjESmjyy/pdDGqoYDx0iAPmfCdC3VXNObmPlh7+NOM3GTEnSddMLmdTXEl7OY/ty3pdBkRrzKS1h3xae1xVIuJHa9ZoXkVbZR0I/ic40qgu0+r3c2tLtJR8Qo4bfiXY58ZYXESmkNxTYvh6vGk0lWcVTqkpOvDDs25lnNmpsZ5aKbtp7+oXbV0Yly5q3uBeAUca9cZ+20jnB53BylMeem7RKbvKq5d5HSZ4xUz39VJjL6z48OhuLwn6CzS4gtL90WB/KnRv6HTycsS08nLKopO0Sk6RbdcdEt9x09JSUlJSUlJaR76ADxnNKfVlT57AAAAAElFTkSuQmCC"/></div><div class="graphic_lgnd">This algorithm describes response-guided induction therapy for sALCL in adults (all disease stages and any ALK status) and post-induction management for patients with limited-stage disease (stage I and II) who have a CR on end-of-induction PET. Refer to related UpToDate material for details of diagnosis, treatment, response assessment, eligibility for autologous HCT, and post-induction management of extensive-stage sALCL in transplant-eligible patients.</div><div class="graphic_footnotes"><p>ALK: anaplastic lymphoma kinase;
BV+CHP: brentuximab vedotin, cyclophosphamide, doxorubicin, prednisone;
CR: complete response;
HCT: hematopoietic cell transplantation;
PET3: positron emission tomography performed after three cycles of induction therapy;
PR: partial responses;
sALCL: systemic anaplastic large cell lymphoma;
SD or PD: stable disease or progressive disease.</p>
<p>* Based on five-point (Deauville) score using Lugano criteria.</p>
<p>¶ The choice of observation versus autologous HCT in this setting must be individualized.</p>
Δ PR with limited residual disease refers to a single site of persistent disease that is amenable to radiation therapy.</div><div id="graphicVersion">Graphic 142614 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
